Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02561832
Title A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide

Olaparib

Carboplatin

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST